anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Sarcopenia has been purported to be a pre-operative risk factor that affects patient outcomes in oncological surgery, but no study as of yet has investigated the effect of sarcopenia in patients with spinal tumours. Psoas muscle measurements, including the psoas muscle index (PMI), are an objective way to determine sarcopenia.
OBJECTIVES: We investigated if PMI could predict post-operative outcomes (length of hospital stay and post-operative complications) in surgically treated spinal tumour patients in a multi-ethnic Asian population.
METHODS: We conducted a retrospective cohort study of patients with spinal tumours who underwent surgery at our tertiary institution from January 2016 to January 2020. PMI was measured on T2-weighted MRI sequences, at the middle of the L3 vertebral body and measurements were collected by 2 independent raters. The primary outcome was length of hospital stay (LOS), and the secondary outcome was post-operative complications. ROC curve was used to attain the cut-off value for PMI and the population was then stratified into 2 groups; sarcopenic if PMI was less than 1.22 and non-sarcopenic if the PMI value was more than or equal to 1.22. Multivariable linear regression was used for LOS, while multivariate logistic regression was used for complications.
RESULTS: 57 patients were included with a mean length of stay of 17.8 days (SD 25.1) and the total number of patients with complications were 20 (35.1 %). Mean LOS was significantly higher in the sarcopenic group compared to the non-sarcopenic group. Univariate analysis confirmed the association of lower psoas muscle index corresponding with longer lengths of stay and this was corroborated in a multivariable linear regression model. There were no significant associations between PMI and postoperative complications.
CONCLUSIONS: Lower PMI values were significantly associated with a longer LOS. PMI may be warranted for risk stratifying Asian spinal tumour patients undergoing surgery.
PCT No. PCT/GB90/00604 Sec. 371 Date Sep. 25, 1991 Sec. 102(e) Date Sep. 25, 1991 PCT Filed Apr. 20, 1990 PCT Pub. No. WO90/12878 PCT Pub. Date Nov. 1, 1990.A novel enhancer, known as the K3'-enhancer, has been identified in the mouse immunoglobulin K locus, downstream of CK. The K3'-enhancer is B cell specific, is some sevenfold stronger than the K-intron enhancer and the region of the enhancer shows striking sequence homologies to the lymphotopic papovavirus, IgH and K-intron enhancers. The novel enhancer allows high level expression both in transfected cell lines and in transgenic mice, and may thus be used to enhance expression of genes in host cells, in vivo and in vitro. The novel enhancer is also found to increase somatic mutation of antibody genes in transgenic mice. The novel enhancer can also be use in gene therapy. Functionally equivalent enhancers are to be expected to occur downstream of CK of the immunoglobulin K locus of other species.
Extracorporeal Membrane Oxygenation (ECMO) is used to provide continuous extracorporeal respiratory and circulatory support for patients with severe cardiopulmonary failure. It is the most important life support method in critical care medicine, and also one of the most complex and expensive treatment methods in intensive care unit (ICU). It takes a lot of resources to maintain. Therefore, it is particularly important to strictly grasp the indications of patients and accurately predict the prognosis of patients to assist clinical decision-making.

Several previous published studies have used clinical scores to predict the prognosis of ECMO patients, but most of them focused on ECMO outcomes in specific patient groups, such as adult respiratory distress syndrome(ARDS), respiratory failure, lung transplantation, cardiogenic shock, and so on. In addition, most of these estimates were calculated using traditional statistical methods and have limited fitting power for data sets with more characteristic variables.

Artificial Intelligence (AI) and Machine Learning (ML) provide a more advanced alternative to traditional statistical methods, and have unparalleled advantages in dealing with data sets with high-dimensional characteristic variables and nonlinear data. And it can self-iterate to improve model performance. In addition, ML, which can process information based on causal or statistical data, may reveal hidden dependencies between clinical indicators and disease prognosis and support clinical decision making, has emerged as the best alternative The primary outcome measures discharged alive from the hospital and died during hospitalization. A total of 69 clinical characteristic indicators were identified based on relevant literature and insights from ECMO experts in critical care medicine. These indicators included demographic data such as age, height, weight, and the medical history of ECMO patients. Additionally, infection indicators were assessed within 24 hours prior to the initiation of ECMO support and within 24 hours after its discontinuation. Furthermore, indicators pertaining to cardiac, renal, and hepatic function, as well as the type of shock (distributive shock, hypovolemic shock, cardiogenic shock, obstructive shock), were included. In addition, the average daily liquid volume within three days after the initiation of ECMO support, the duration of ECMO support, and the ICU length of stay were also considered.
Infectious diseases severely threaten human health, and traditional treatment techniques face multiple limitations. As an important component of immune cells, macrophages display unique biological properties, such as biocompatibility, immunocompatibility, targeting specificity, and immunoregulatory activity, and play a critical role in protecting the body against infections. The macrophage membrane-coated nanoparticles not only maintain the functions of the inner nanoparticles but also inherit the characteristics of macrophages, making them excellent tools for improving drug delivery and therapeutic implications in infectious diseases (IDs). In this review, we describe the characteristics and functions of macrophage membrane-coated nanoparticles and their advantages and challenges in ID therapy. We first summarize the pathological features of IDs, providing insight into how to fight them. Next, we focus on the classification, characteristics, and preparation of macrophage membrane-coated nanoparticles. Finally, we comprehensively describe the progress of macrophage membrane-coated nanoparticles in combating IDs, including drug delivery, inhibition and killing of pathogens, and immune modulation. At the end of this review, a look forward to the challenges of this aspect is presented.
f) (1,2,4) TRIAZOLO (4.3-a) DIAZEPINES IN CASE OF PRESENCE OF AT LEAST ONE ASYMMETRIC CENTER, ENANTIOMERS, RACEMATES AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, METHOD OF PREPARATION THEREON, AND PHARMACEUTICAL COMPOSITION INHIBITING THROMBOCYTE ACTIVATION FACTOR. FIELD: pharmaceutical industry. SUBSTANCE: present invention describes new triazolo [4,3- a] [1,4] benzodiazepines or thieno [3,2-f] [1,2,4] triazolo [4,3-a] diazepines of general formula I:   wherein X is -CH=CH- or S; R 1  is lower alkyl or trifluoromethyl; R 2  is theorine or fluorine; R 3  is radical of formula: R 4 -(CH 2 ) n -C≡C- or R 5 -O-CH 2 -C≡C- in which n is integer of 0.1 or 2; s is 0 or 1; R 4  is phenyl or mono-, di- or tricyclic 5-6 membered heterocyclic radical containing O or S as heteroatoms and/or nitrogen atoms unsubstituted or substituted by lower alkoxy, oxo, oxy group or chlorine; R 5  is phenyl or pyridyl provided that when is 0, R 4  should be attached to carbon bond through carbon and R 5  is always attached to oxygen bond through carbon and if at least one ASYMMETRIC center is present, said radical is attached to enantiomers, racemates and pharmaceutically acceptable acid addition salts thereof which exhibit properties of thrombocyte activation factor antagonists and respectively having antiprotector, immunological and antishock properties as well as properties that inhibit/of the organs to be transplanted, and pharmcompositions based thereon. Present invention also describes compounds of formula I in which R 3  C=CH. Compounds of formula I or pharmaceutically acceptable acid addition salts thereof are prepared by reaction of compound of formula II with compound of formula: C≡CH. is which R 4 -Y is as defined in claim 1, and Y is bromine or iodine, and optionally for preparation compound of formula I in which s is 1 and R 4  is other than residue containing main nitrogen atom, the compound of formula I in which s is O and R 4  is other than residue containing main nitrogen atom, peracid and/or the resulting compound of formula I is optionally transformed into pharmaceutically acceptable acid addition salt thereof. EFFECT: improved properties of the title compounds. 18 cl, 7 tbl
Subacromial bursitis is one of the major causes of chronic refractory shoulder pain. It can cause patients with shoulder pain when shoulder exercise and heavy lifting and limiting the range of motion. It can also influence the sleep quality due to pain symptoms of the shoulder. Usually, these patients had limited response to medication and physical modality. Steroid injection was often adopted for intervention, but the adverse effects should be considered. Therefore, prolotherapy was taken as an alternative treatment for chronic subacromial bursitis. It involves the injection of small volumes of an irritant agent, most commonly a hyperosmolar dextrose solution, at the lesion site. Hyperosmolar dextrose appears to be the most commonly used agent today. The aim of this study is to investigate hypertonic injections in subacromial bursitis patients about clinical and ultrasound image presentation. The investigators conducted a double-blinded randomized controlled trial for 60 participants with chronic shoulder pain for 3 months with subacromial bursitis. In the study group, the echo guide 20% dextrose water was injected into the lesion site, and the control group received the echo guide steroid injection. ROM, SPADI, VAS, x-ray, and ultrasound data were obtained at baseline. At weeks 2, 6, 12, ROM, SPADI, VAS, and ultrasound data were evaluated. The ANOVA and independent t-test are applied for analysis by SPSS 20.0 with a P value less than 0.05 as statistical significance.
Recurrent abdominal pain (RAP) is the most common type of pain in school age children and young adolescents. Previous studies suggest that stress plays an important role in the activation of specific cells that can produce pain within the stomach and intestines. Medication is the standard approach to the treatment of RAP in children. Although medication is helpful for many children, medication alone is not always enough. Biofeedback trains individuals to use relaxation strategies effectively to relieve emotional and physical symptoms, and has been used successfully for stress and pain reduction with both children and adults. It has shown promising results when used alone in the treatment of children with RAP. Research is needed, however, to determine whether biofeedback training is helpful when used in conjunction with medication. Information about how biofeedback training affects the central nervous system and the cells that produce pain also would be useful in refining treatments for this large group of children. The current research will be done in three steps, with Phase 1 designed to evaluate the time, resources, technical support, and sample size needed for successful completion of the full research study. Twenty children (ages 8-18) with eosinophilic duodenitis, a specific form of RAP, will be enrolled and randomly assigned to one of two groups: 1) Standard of Care; or 2) Biofeedback (standard medical care plus 10 sessions of biofeedback training). Measures of pain, functional disability, quality of life, physiological arousal, and global treatment response will be collected pre- and post-intervention, as well as 3 and 6 months later. Data collected will be used to determine how many participants will be needed for the full research study. If biofeedback training is ultimately found to be a positive addition to standard medical treatment, this could lead to improved health outcomes for children with RAP. This information also could result in greater treatment efficiency and reduced health care costs for families, insurance providers, and the hospital system.
BACKGROUND: Dyslexia is a neurodevelopmental disorder that causes a pattern of learning difficulties that can be characterized by deficits in word reading accuracy, speed or fluency, and reading comprehension. Due to all this damage, emotional difficulties have been described in the literature mainly for childhood and adolescence. Within this emotional component, personality can be included. In Brazil, at the time of carrying out this research, no research had been found that investigated the personality of dyslexic adults. Thus, the present study aimed to investigate the personality of Brazilian adults with dyslexia.
METHODS: A semi-structured interview was administered and the Factorial Personality Battery, based on the Big Five personality traits. The sample was composed of two groups: one with dyslexia and another control. The first was formed by nine participants, aged between 18 and 47 (M = 31.7; standard deviation (SD) = 11.8), six of whom were women. The control group was formed by 60 participants, aged between 18 and 45 years (M = 26.4; SD = 8.8), 38 of whom were women.
RESULTS: The data did not show significant differences between the groups in most of the analyzed factors and subfactors. Increased rates of "passivity/lack of energy" and lowered rates of "openness to new ideas" were identified in the group with dyslexia.
CONCLUSION: These results could be useful for describing personality profiles in dyslexic adults, with these descriptions possibly providing clinical support for diagnoses and intervention procedures.
Clonidine transdermal system is a multi-layered film, 0.25 mm thick, containing clonidine as the active agent. The system areas are 3.33 cm2 (0.1 mg/day), 6.67 cm2 (0.2 mg/day), and 10.0 cm2 (0.3 mg/day) and the amount of drug released is directly proportional to the area (see DESCRIPTION: Release Rate Concept). The composition per unit area is the same for all three doses.

Proceeding from the visible surface towards the surface attached to the skin, there are three consecutive layers: 1) a backing layer of pigmented polyethylene and polyester film, 2) a solid matrix reservoir of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide, 3) an adhesive formulation of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide. Prior to use, a protective slit release liner of polyester that covers the adhesive formulation layer is removed.

Clonidine transdermal systems are packaged with additional pieces of protective film above and below the system within each pouch. These pieces of protective film are removed and discarded at the time of use.

Cross Section of the System:
The invention discloses a black soya bean and cyclocarya paliurus effervescent tablet. The effervescent tablet is prepared from the following raw materials in parts by weight: 100 to 120 parts of cyclocarya paliurus, 10 to 12 parts of green tea powder, 10 to 15 parts of black soya bean, 1 to 2 parts of five spice powder, a proper amount of sodium bicarbonate, 4 to 5 parts of buckwheat leaf, 2 to 3 parts of corn silk, 3 to 4 parts of privet leaf, 1 to 2 parts of abrus cantoniensis hance, 2 to 3 parts of jerusalem artichoke, 1 to 2 parts of mulberry leaf, 3 to 4 parts of cynanchum atratum, and a proper amount of acid powder and yellow wine. The preparation method comprises the following steps: freeze-drying fresh cyclocarya paliurus, then subjecting the dried cyclocarya paliurus to ultramicro grinding, mixing the cyclocarya paliurus powder with sodium bicarbonate, pressing the mixed powder into tablets, and finally covering the tablets with acid powder made of rice vinegar and other components. The effervescent tablet has the advantages of simple technology and reasonable formula. When a finished effervescent tablet is soaked in hot water, the acid powder in the mid-outer layer of the tablet will be rapidly dissolved, thus the water will be in a weak acidic state, so the dissolution of the drug in the inner layer of the tablet is accelerated. The effervescent tablet is rich in nutrients and has a prominent healthcare effect due to the addition of green tea powder, black soya bean, walnut kernel, and traditional Chinese herbals.
Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
Anterior discectomy and fusion (ACDF) is in Norway currently the most common operative method against cervical radiculopathy, caused by disc herniation and/or spondylosis. In the last decade cervical arthroplasty has emerged as a new alternative operative method. Arthroplasty is claimed to preserve the natural motion of the spine, thereby preventing adjacent level disc disease and providing better clinical results. However, this hypothesis has not yet been adequately proven. In our study, we will prove if there is any real difference in terms of clinical effect between cervical arthroplasty and ACDF.We will also compare the overall costs of the two methods, including cost-utility analyses. Moreover, we will study the development of adjacent level disease by use of MRI scans, and analyze cervical spine motion and disc height by use of Distortion Compensated Roentgen Analysis (DCRA).
In one aspect, hollow nanoparticles are described herein. In some embodiments, a hollow nanoparticle comprises a metal shell and a cavity substantially defined by the shell, wherein the shell has a thickness greater than or equal to about 5 nm and the cavity has a curved surface. In another aspect, methods of making hollow nanoparticles are described herein. In some embodiments, a method of making hollow nanoparticles comprises forming a plurality of gas bubbles and forming a shell on the surface of at least one of the plurality of gas bubbles, wherein at least one of the gas bubbles is electrochemically generated. In another aspect, composite particles are described herein. In some embodiments, a composite particle comprises at least one nanoparticle and a polycrystalline metal shell substantially encapsulating at least one nanoparticle, wherein at least one surface of at least one nanoparticle is not in contact with the shell.
Cocaine likely creates its reinforcing and addictive effects by increasing levels of dopamine, a brain neurotransmitter. GABA agonists are chemicals that have the opposite effect by inhibiting the release of dopamine. Increasing GABA activity may result in greater inhibition of dopamine systems, which may lead to new treatments for cocaine abuse. The purpose of this study is to determine whether pretreatment with GABA agonists reduces the psychological and physiological reinforcing effects of cocaine. Specifically, the study will look at three different GABA agonists: tiagabine, baclofen, and trazolam.

This double-blind, placebo-controlled study will involve three separate experimental phases; each phase will last 4 weeks and will test one of three GABA agonists (tiagabine, baclofen, or trazolam). Daily testing sessions will last approximately 6 hours. One of four GABA agonist dose treatments will be administered. Participants will then be introduced to a sample dose of intranasal cocaine. This will allow the participants to become acquainted with the drug effects of the corresponding cocaine dose for that day (0.444, 5, 10, or 20 mg). Subjective, physiological, and performance measures will be obtained. This will be followed by a period of cocaine self-administration. Participants will be given the opportunity to work on a computer to obtain additional single unit doses of cocaine. A total of 8 unit doses of cocaine will be available during each daily session. At the end of the daily session, additional subjective measures will be evaluated with questionnaires. Overall, a total of 16 GABA agonist-cocaine dose combinations will be administered on 16 different days. A subgroup of participants will also undergo similar procedures with the option to acquire money instead of cocaine. At the end of the study, all participants will be offered a referral to an appropriate drug-abuse treatment program.
Famotidine is indicated in:

Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks.   
Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year.   
Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.   
Short term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, CLINICAL STUDIES).   
Famotidine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, CLINICAL STUDIES).   
Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, CLINICAL STUDIES).
Risk Summary

Data from published literature reports with oral preparations of diclofenac indicate the presence of small amounts of diclofenac in human milk (see Data). There are no data on the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% and any potential adverse effects on the breastfed infant from the DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% or from the underlying maternal condition.

Data

One woman treated orally with a diclofenac salt, 150 mg/day, had a milk diclofenac level of 100 mcg/L, equivalent to an infant dose of about 0.03 mg/kg/day. Diclofenac was not detectable in breast milk in 12 women using diclofenac (after either 100 mg/day orally for 7 days or a single 50 mg intramuscular dose administered in the immediate postpartum period). The relative bioavailability for DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is <1% of a single 50 mg diclofenac tablet.